{"id":61873,"date":"2026-03-30T19:13:26","date_gmt":"2026-03-30T11:13:26","guid":{"rendered":"https:\/\/flcube.com\/?p=61873"},"modified":"2026-03-30T19:13:27","modified_gmt":"2026-03-30T11:13:27","slug":"medtronics-stealth-axis-surgical-system-gains-fda-approval-for-cranial-and-ent-procedures-expanding-beyond-spine","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61873","title":{"rendered":"Medtronic\u2019s Stealth AXiS Surgical System Gains FDA Approval for Cranial and ENT Procedures, Expanding Beyond Spine"},"content":{"rendered":"\n

Medtronic plc<\/strong> (NYSE: MDT<\/a>) announced it has received U.S. Food and Drug Administration (FDA) marketing approval<\/strong> for its Stealth AXiS\u2122 surgical system<\/strong> in cranial and ear, nose, and throat (ENT) surgeries<\/strong>, following its initial spinal surgery clearance in February 2026<\/strong>. The unified platform\u2014integrating surgical planning, real-time navigation, and robotic assistance<\/strong>\u2014is designed to enhance precision, reduce procedural variability, and deliver actionable intraoperative insights during complex head and neck interventions.<\/p>\n\n\n\n

Regulatory Milestones<\/h2>\n\n\n\n
Indication<\/th>FDA Status<\/th>Date<\/th><\/tr><\/thead>
Spinal Surgery<\/strong><\/td>Cleared<\/td>February 2026<\/td><\/tr>
Cranial & ENT Surgery<\/strong><\/td>Approved<\/strong><\/td>March 2026<\/td><\/tr>
Platform Name<\/strong><\/td>Stealth AXiS\u2122<\/td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

This dual-indication authorization establishes Stealth AXiS as Medtronic\u2019s first cross-specialty intelligent surgical platform<\/strong>, bridging neurosurgery, ENT, and spine care under a single technological architecture.<\/p>\n\n\n\n

System Capabilities<\/h2>\n\n\n\n

The Stealth AXiS system<\/strong> combines three core functions into one seamless workflow:<\/p>\n\n\n\n